Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza
Dagmar
D
Clinical Pharmacology, Bayer Schering Pharma AG, 42096 Wuppertal, Germany. dagmar.kubitza@bayerhealthcare.com
Becka
Michael
M
Mueck
Wolfgang
W
Halabi
Atef
A
Maatouk
Haidar
H
Klause
Norbert
N
Lufft
Volkmar
V
Wand
Dominic D
DD
Philipp
Thomas
T
Bruck
Heike
H
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D015331:Cohort Studies; D003404:Creatinine / Q000378:metabolism; D065427:Factor Xa Inhibitors; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009025:Morpholines / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051437:Renal Insufficiency / Q000378:metabolism*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000493:pharmacokinetics* / Q000494:pharmacology*
D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban; D003404:Creatinine